Iovance Biotherapeutics, Inc. (IOVA)
14.17
-0.04
(-0.32%)
USD |
NASDAQ |
Oct 05, 12:37
Iovance Biotherapeutics Profit Margin (Quarterly) : -47.64% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -47.64% |
| March 31, 2026 | -110.7% |
| December 31, 2025 | -82.92% |
| September 30, 2025 | -135.3% |
| June 30, 2025 | -186.2% |
| March 31, 2025 | -235.5% |
| December 31, 2024 | -106.6% |
| Date | Value |
|---|---|
| September 30, 2024 | -142.7% |
| June 30, 2024 | -312.2% |
| March 31, 2024 | -15.80K% |
| December 31, 2023 | -24.15K% |
| September 30, 2023 | -24.26K% |
| June 30, 2023 | -44.76K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| AVITA Medical, Inc. | -35.31% |
| Amgen, Inc. | 23.59% |
| Halozyme Therapeutics, Inc. | 47.80% |
| Neurocrine Biosciences, Inc. | 15.06% |
| Editas Medicine, Inc. | -153.3% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -40.70% |
| Return on Assets | -31.70% |
| Return on Invested Capital | -38.03% |
| Gross Profit Margin (Quarterly) | 46.54% |
| Operating Margin (Quarterly) | -52.26% |
| Return on Net Operating Assets | -49.41% |